B Meyer-Wyss
Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis
Meyer-Wyss B, Renner E, Arn M, Meyenberger C, Borovicka J, Rossi L, Criblez D, Oneta C, Gonvers J, Rammert C, Mullhaupt B, Helbling B, Egger H, Rich P, Swiss Association for the Study of the Liver (SASL). Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. Journal of viral hepatitis 2006; 13:457-65.
Jul 1, 2006Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis
Jul 1, 2006Journal of viral hepatitis 2006; 13:457-65
Meyer-Wyss B, Renner E L, Arn M, Meyenberger Christa, Borovicka Jan, Rossi L, Criblez D, Oneta C, Gonvers J-J, Rammert C, Mullhaupt B, Helbling B, Egger Hp, Rich P, Swiss Association for the Study of the Liver (SASL)
Comparison between esophageal Wallstent and Ultraflex stents in the treatment of malignant stenoses of the esophagus and cardia
Dorta G, Wiesel P, Weber B, Scheurer U, Protiva P, Michetti P, Meyer-Wyss B, Meyenberger C, Meier R, Lang C, Lammer F, Koelz H, Felley C, Bühler H, Blum A, Binek J, Vogel S. Comparison between esophageal Wallstent and Ultraflex stents in the treatment of malignant stenoses of the esophagus and cardia. Endoscopy 1997; 29:149-54.
Mar 1, 1997Comparison between esophageal Wallstent and Ultraflex stents in the treatment of malignant stenoses of the esophagus and cardia
Mar 1, 1997Endoscopy 1997; 29:149-54
Dorta G, Wiesel P, Weber B, Scheurer U, Protiva P, Michetti P, Meyer-Wyss B, Meyenberger Christa, Meier R, Lang C, Lammer F, Koelz H R, Felley C P, Bühler H, Blum A L, Binek Janek, Vogel S